Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...
All content for Business Trip is the property of Greg Kubin & Matias Serebrinsky and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Business Trip
56 minutes
1 year ago
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting. In this episode, we discuss: The FDA advisory committee process and its implications for drug approvalsFunctional unblinding and expectancy effects in psychedelic c...
Business Trip
Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...
